Does a GLP-1 Cause Gastroparesis?
GLP-1 medications slow how fast your stomach empties, and every label says so. But gastroparesis isn't listed as a side effect on any of the four major labels. A small number of people develop symptoms severe enough to be diagnosed with it, and in published case reports those symptoms resolved after the drug was stopped. So it's possible, it appears to be uncommon, and the evidence is still thin.
Here's where gastroparesis actually shows up on the labels:
The Ozempic, Zepbound, and Mounjaro Medication Guides also ask you to tell your prescriber before starting if you have severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis).
Slow Emptying vs. Gastroparesis: What's the Difference?
NIDDK defines gastroparesis as a disorder that slows or stops the movement of food from your stomach to your small intestine. It's diagnosed with testing, not just symptoms.
A GLP-1 drug slowing the stomach is expected. It's part of why you feel full sooner and stay full longer. For most people the slowdown is modest and doesn't cause lasting trouble. The concern is the smaller group whose stomach slows enough to cause ongoing symptoms like vomiting, early fullness, and pain.
One wrinkle worth knowing. NIDDK's gastroparesis pages, last reviewed in 2018 and written before these drugs were widely used for weight loss, say certain medicines may delay gastric emptying and cause symptoms similar to gastroparesis, and then add that "these medicines do not cause gastroparesis." GLP-1 drugs aren't on that list. We point this out because you'll see the terms used loosely online, and doctors don't always agree on what to call medication-related slowing.
How Much Does a GLP-1 Slow the Stomach?
Less than most people imagine, at least on average. Think of your stomach as the first stop on a conveyor belt. GLP-1 drugs slow that first stop down.
A 2024 meta-analysis of 5 scintigraphy studies (247 people) found half of a solid meal took about 36 minutes longer to leave the stomach on a GLP-1 than on placebo, 138 versus 95 minutes. A 2026 meta-analysis of 10 studies (300 people) found about 74 minutes longer on average, with a trend toward larger delays for short-acting drugs and in the first 10 weeks, and rated its evidence very low certainty. A 20-week trial of semaglutide 2.4 mg in 72 adults with obesity found no evidence of delayed emptying at week 20 using paracetamol absorption, an indirect measure. The Zepbound and Mounjaro labels say the delay is largest after the first dose and diminishes over time.
The paracetamol method used in that 20-week trial is less sensitive to solid-food emptying, which is one reason the studies don't line up perfectly. That trial was funded by the drug's manufacturer. And the two meta-analyses don't fully agree: Hiramoto's team found that treatment duration didn't significantly change the delay.
Why would the effect fade? Researchers call it tachyphylaxis: the body adapts to steady GLP-1 exposure. A small 2011 study that infused natural GLP-1 into 9 healthy volunteers found the delay in gastric emptying is subject to rapid tachyphylaxis. A 2024 review in the Journal of Clinical Endocrinology and Metabolism also listed tachyphylaxis observed with prolonged treatment among the factors to consider. That 2011 study used infused GLP-1, not the weekly injections people take today, so it's a clue rather than proof.
The practical point: the tirzepatide labels say the delay is largest after the first dose, and surgical guidance treats the dose escalation phase as higher risk for delayed emptying. That lines up with when nausea tends to hit, which we covered in our guide to GLP-1 nausea.
How Strong Is the Link to Gastroparesis?
The most quoted number comes from a 2023 JAMA research letter. It compared people using GLP-1 drugs for weight loss with people taking bupropion-naltrexone, another weight-loss medication. It found a hazard ratio of 3.67 for gastroparesis (95% CI, 1.15 to 11.90).
That sounds big. Here's the context that usually gets left out:
- The comparison group had just 3 gastroparesis events. The semaglutide group had 4. Most events, 66, came from liraglutide, an older drug, largely because far more people in the study were taking it.
- The rates were low in every group: 9.1 per 1,000 person-years on semaglutide, 7.3 on liraglutide, and 3.1 on bupropion-naltrexone.
- Gastroparesis was defined by a billing code or a prescription for a promotility drug, not by confirmed testing in everyone.
- The authors themselves described these events as rare.
So it's a real signal, and a very imprecise number. It suggests the risk may be higher than with bupropion-naltrexone, but it can't tell us your personal risk.
Is Gastroparesis From a GLP-1 Reversible?
In the cases that have been published, yes. But the evidence is small.
The clearest example is a 2021 report of two women with type 2 diabetes. One was taking semaglutide, the other dulaglutide. Both had gastric emptying tests showing food retained at 4 hours. After stopping the drug, both tests returned to normal: from 24 percent retained to 6 percent after 6 weeks off semaglutide, and from 35 percent to 3 percent after 4 weeks off dulaglutide. The authors concluded that medication-induced gastroparesis is reversible and that stopping the medication is generally curative.
A 2026 systematic review pulled together 12 case reports describing 13 patients. Stopping the GLP-1 led to symptom resolution in all of them. Not every case was confirmed with a gastric emptying scan, though.
Two honest caveats. Case reports tend to get published when there's a clear story, so they may not represent everyone. And we couldn't find a larger study that followed people after stopping to see how often symptoms persist. "Reversible in published cases" is accurate. "Always reversible" isn't something anyone can promise yet.
How Long Does It Take to Go Away After Stopping?
Timing depends partly on how long the drug stays in your body. The Wegovy label says semaglutide will be present in the circulation for about 5 to 7 weeks after the last injectable dose of 2.4 mg. Tirzepatide's half-life is shorter, about 5 to 6 days per the Zepbound label. In the two cases above, testing was back to normal at 4 to 6 weeks. That's two people, so treat it as a rough guide, not a timeline.
And please don't stop your medication on your own to test this. That decision belongs with your prescriber.
What Are the First Signs of Gastroparesis?
NIDDK lists these symptoms of gastroparesis:
- Feeling full soon after starting a meal
- Feeling full long after eating a meal
- Nausea
- Vomiting
- Too much bloating
- Too much belching
- Pain in your upper abdomen
- Heartburn
- Poor appetite
Here's the tricky part. Several of these, like early fullness and a smaller appetite, are exactly what a GLP-1 is supposed to do. What's worth paying attention to is a change in pattern: vomiting that keeps coming back, food you can feel sitting there many hours later, or symptoms that get worse over time instead of settling after a dose increase.
Heartburn is on that list for a reason. A fuller stomach puts more pressure on the lid at the top of it. We explained that connection in Does a GLP-1 Cause Acid Reflux or Heartburn?
How Gastroparesis Is Diagnosed: The 4-Hour Test
The standard test is gastric emptying scintigraphy. NIDDK describes it this way: you eat a bland meal, such as eggs or an egg substitute, that contains a small amount of radioactive material, and a scanner tracks how quickly it leaves your stomach. The scan usually takes about 4 hours. That's the "4-hour test" people search for.
NIDDK also describes a breath test, which collects samples over about 4 hours, and a wireless motility capsule, sometimes called a SmartPill, that you swallow and that measures how fast it moves through your digestive tract.
One thing to raise with your doctor: because GLP-1 drugs slow emptying, being on one at the time of the test can affect the result. Ask whether and how to adjust before testing.
What Can Be Mistaken for Gastroparesis?
The most common look-alike is indigestion. NIDDK notes that indigestion may be confused with other conditions, such as acid reflux or gastroparesis. Among people in the United States who see a doctor about indigestion, about 7 in 10 are diagnosed with functional dyspepsia, meaning no clear cause is found. That's why testing matters. Symptoms alone can't tell the conditions apart.
What Helps: Eating With a Slower Stomach
We couldn't find a trial testing any eating plan specifically for GLP-1-related slow emptying. But NIDDK's eating advice for gastroparesis is a sensible place to start if your stomach feels slow. It recommends that people:
- Eat five or six small, nutritious meals a day instead of two or three large ones
- Eat foods low in fat and fiber
- Chew food thoroughly
- Eat soft, well-cooked foods
- Avoid carbonated, or fizzy, drinks
- Avoid alcohol
- Drink plenty of water or liquids that contain glucose and electrolytes
- Take a gentle walk after a meal
- Avoid lying down for 2 hours after a meal
Notice the fiber point. It's the opposite of the usual advice for constipation, which is also common on these drugs. If you're dealing with both, that's a conversation to have with your doctor or a dietitian rather than something to guess at.
What Foods Make Gastroparesis Worse?
NIDDK suggests avoiding foods and drinks that are high in fat, high in fiber, or hard to chew, along with fizzy drinks and alcohol. High-fat and high-fiber foods tend to stay in the stomach longer. On a GLP-1, a large, rich meal is often the one that sits the longest.
How to Lower Your Risk on Zepbound or Another GLP-1
Nothing has been proven to prevent gastroparesis on these drugs. What we do know is that the stomach slows most after the first dose and after dose increases. So a few things are reasonable to discuss with your prescriber:
- The pace of dose increases. If symptoms haven't settled, ask whether it makes sense to stay at your current dose longer before moving up.
- Smaller meals. Stop eating when you first feel full. On these drugs, that signal arrives earlier than you're used to.
- Your history. If you've had gastroparesis before, or have diabetes-related nerve damage, tell your prescriber. The labels say these drugs are not recommended with severe gastroparesis.
Surgery, Endoscopy, and Sedation
This is the most important practical point in this article. All four labels warn that there have been rare postmarketing reports of pulmonary aspiration in patients on GLP-1 drugs who had general anesthesia or deep sedation and still had stomach contents despite reportedly following fasting instructions. Aspiration means stomach contents getting into the lungs.
The labels ask patients to tell their healthcare providers before any planned surgery or procedure. A 2024 multisociety guidance from gastroenterology, bariatric surgery, and anesthesia groups recommends shared decision-making, and in some higher-risk situations a liquid diet for at least 24 hours before the procedure. It lists the dose escalation phase, higher doses, and ongoing GI symptoms among the risk factors.
So if you have a colonoscopy, endoscopy, or surgery coming up, make sure both your prescriber and the team doing the procedure know you're on a GLP-1.
When to Call a Doctor Right Away
NIDDK says to seek a doctor's help right away if you have:
- Severe pain or cramping in your abdomen
- Blood glucose levels that are too high or too low
- Red blood in your vomit, or vomit that looks like coffee grounds
- Sudden, sharp stomach pain that doesn't go away
- Vomiting for more than an hour
- Feeling extremely weak or fainting
- Difficulty breathing
- Fever
Signs of dehydration, like extreme thirst, dark urine, or dizziness, also need prompt attention. The GLP-1 labels add that severe stomach pain that won't go away, sometimes spreading to the back, can be a sign of pancreatitis. We covered the full list of warning signs in our GLP-1 digestive side effects guide.
The Better Question
Let's step back.
Most of the fear around GLP-1s and gastroparesis comes from a real place. These drugs do change how the upper digestive tract moves. For most people that change is modest and fades. For a few, it isn't, and those people deserve to be taken seriously and tested rather than told it's just an adjustment phase.
So the better question isn't only "will this drug give me gastroparesis?" It's "what was my digestion like before I started, and what's changed?" Knowing how you felt before, including any reflux, bloating, or early fullness, gives you and your doctor something to compare against. It's also what makes a real change easier to spot.
That habit of paying attention to your own digestion, rather than just reacting to symptoms, is the whole idea behind our brand.
Our products come from that everyday view of digestion, and they are not for gastroparesis. We developed Re:flux to support upper digestive comfort for people with occasional heartburn. Atrantil is a polyphenol formula for occasional bloating and gas. Neither has been studied in people taking GLP-1 drugs. Neither is a treatment for gastroparesis or any other diagnosed condition, or for any medication side effect. If you have symptoms of gastroparesis, get evaluated first. Anything you add while on a prescription should go past your prescriber. The reasoning behind Re:flux is on The Acid Truth.
Understanding how your own digestion works helps you ask better questions and have better conversations with your healthcare provider. If you want a starting point, take the quiz. For more on how a slow stomach feeds reflux, see Why Motility Matters.
About Re:garding Your Gut
Re:garding Your Gut is a polyphenol-powered gut health brand founded by Kenneth Brown, MD, a board-certified gastroenterologist with more than 20 years in practice. The product family includes Atrantil for bloating and gas, Re:flux for acid reflux, and Re:balance for microbiome support.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is educational and is not medical advice, and it is not a substitute for your medication's prescribing information or your prescriber's advice. Do not start, stop, or change the dose of a prescription medication based on this article. Talk to your healthcare provider before adding any supplement while taking a GLP-1 medication.
